Subcutaneous low doses of interleukin-2 and recombinant interferon alpha with carboplatin and vinblastine in patients with advanced melanoma
Φόρτωση...
Ημερομηνία
Συγγραφείς
Bafaloukos, D.
Fountzilas, G.
Skarlos, D.
Pavlidis, N.
Bakoyiannis, C.
Karvounis, N.
Kosmidis, P.
Τίτλος Εφημερίδας
Περιοδικό ISSN
Τίτλος τόμου
Εκδότης
Περίληψη
Τύπος
Είδος δημοσίευσης σε συνέδριο
Είδος περιοδικού
peer-reviewed
Είδος εκπαιδευτικού υλικού
Όνομα συνεδρίου
Όνομα περιοδικού
Oncology
Όνομα βιβλίου
Σειρά βιβλίου
Έκδοση βιβλίου
Συμπληρωματικός/δευτερεύων τίτλος
Περιγραφή
Twenty-three patients with advanced melanoma were treated with a combination of subcutaneous recombinant human interleukin-2 (IL-2), and recombinant interferon alpha-2a (IFN-alpha) with chemotherapy consisting of four cycles of carboplatin (300 mg/m2, day 1) and vinblastine (6 mg/m2, day 1), every 28 days (CV-IL-IF). IL-2 was given at a dose of 4.5 x 10(6) U twice daily on days 3-6 and days 21-24 of each cycle; IFN-alpha dose was 4.5 x 10(6) U, starting on day 2, thrice weekly. Immunotherapy was intended to continue for 6 months. Of the 23 analyzed patients, 4 (17%) achieved an objective response, including 1 complete and 3 partial responses, in nonvisceral metastatic disease. The median time to progression was 5 months and the median survival from onset of the treatment 6 months (range 1-14 months). Four patients discontinued the treatment, due to nonhaematologic toxicity; 3 for severe weakness and the 4th patient for long-lasting CNS side-effects. Other grade 3-4 toxicities included weight loss (22%), nausea and vomiting (17%) and alopecia (13%). The haematologic toxicity was acceptable. No toxic death was noted. It is concluded that the CV-IL-IF regimen has limited activity and moderate toxicity.
Περιγραφή
Λέξεις-κλειδιά
Adult, Aged, Antineoplastic Agents, Phytogenic/administration & dosage, Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use, Carboplatin/administration & dosage, Chemotherapy, Adjuvant, Female, Humans, Injections, Subcutaneous, Interferon-alpha/administration & dosage, Interleukin-2/administration & dosage, Male, Melanoma/*drug therapy/secondary, Middle Aged, Prospective Studies, Skin Neoplasms/*drug therapy/pathology, Survival Analysis, Treatment Outcome, Vinblastine/administration & dosage
Θεματική κατηγορία
Παραπομπή
Σύνδεσμος
http://www.ncbi.nlm.nih.gov/pubmed/9428375
http://content.karger.com/ProdukteDB/produkte.asp?doi=10.1159/000011834
http://content.karger.com/ProdukteDB/produkte.asp?doi=10.1159/000011834
Γλώσσα
en
Εκδίδον τμήμα/τομέας
Όνομα επιβλέποντος
Εξεταστική επιτροπή
Γενική Περιγραφή / Σχόλια
Ίδρυμα και Σχολή/Τμήμα του υποβάλλοντος
Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής